<b>Health insurance; treatment of cancer and certain diseases; coverage of certain medications.</b> Requires an insurer, corporation providing preferred provider subscription contracts, or health maintenance organization that provides coverage for drugs approved by the Food and Drug Administration and prescribed for the treatment of cancer or diseases of the blood to allow, at the patient's direction, (i) provider-administered drugs for such treatment to be dispensed by an in-network treating provider consistent with a provider agreement; (ii) provider-administered drugs for such treatment to be dispensed by an in-network treating provider when there is a documented delay of at least three days in the delivery of a medication from the designated specialty pharmacy; and (iii) self-administered drugs for such treatment to be sent to the pharmacy of the patient's choosing.
Raw source record
{
"id": 85691,
"url": "https:\/\/www.richmondsunlight.com\/bill\/2026\/sb642\/",
"tags": {
"146678": "health insurance",
"146679": "pharmacies",
"146680": "prescription drugs",
"146681": "delivery",
"146682": "freedom of choice",
"146683": "pharmacy benefits"
},
"text": [
{
"date": "2026-01-14",
"number": "SB642",
"pdf_url": "https:\/\/downloads.richmondsunlight.com\/bills\/2026\/sb642.pdf"
},
{
"date": "2026-01-27",
"number": "SB642S1"
},
{
"date": "2026-02-09",
"number": "SB642S2"
}
],
"type": "bill",
"year": 2026,
"video": null,
"number": "sb642",
"patron": "Pillion, Todd",
"status": "failed committee",
"chamber": "senate",
"changes": null,
"outcome": "failed",
"related": [
{
"id": 84051,
"name": "Commerce and Labor",
"year": 2026,
"count": 2,
"number": "sb161",
"status": "signed by governor",
"catch_line": "Health insurance; limit on cost-sharing payments for prescription drugs under certain plans.",
"date_introduced": "January 07, 2026"
},
{
"id": 85956,
"name": "Commerce and Labor",
"year": 2026,
"count": 2,
"number": "hb1450",
"status": "signed by governor",
"catch_line": "Health insurance; claims experience information, delayed effective date.",
"date_introduced": "January 23, 2026"
},
{
"id": 85391,
"name": "Commerce and Labor",
"year": 2026,
"count": 2,
"number": "sb413",
"status": "incorporated",
"catch_line": "Health insurance; ensuring fairness in cost-sharing; pharmacy benefits managers; compensation and duties: civil penalty.",
"date_introduced": "January 13, 2026"
},
{
"id": 84462,
"name": "Commerce and Labor",
"year": 2026,
"count": 2,
"number": "hb625",
"status": "signed by governor",
"catch_line": "Health insurance; limit on cost-sharing payments for prescription drugs under certain plans.",
"date_introduced": "January 13, 2026"
},
{
"id": 84573,
"name": "Appropriations",
"year": 2026,
"count": 2,
"number": "hb736",
"status": "signed by governor",
"catch_line": "Health insurance; required provisions regarding prior authorization for prescription drugs.",
"date_introduced": "January 13, 2026"
}
],
"summary": "<b>Health insurance; treatment of cancer and certain diseases; coverage of certain medications.<\/b> Requires an insurer, corporation providing preferred provider subscription contracts, or health maintenance organization that provides coverage for drugs approved by the Food and Drug Administration and prescribed for the treatment of cancer or diseases of the blood to allow, at the patient's direction, (i) provider-administered drugs for such treatment to be dispensed by an in-network treating provider consistent with a provider agreement; (ii) provider-administered drugs for such treatment to be dispensed by an in-network treating provider when there is a documented delay of at least three days in the delivery of a medication from the designated specialty pharmacy; and (iii) self-administered drugs for such treatment to be sent to the pharmacy of the patient's choosing.",
"version": "SB642S2",
"copatron": [
{
"shortname": "melocke",
"partisanship": 33,
"name_formatted": "Sen. Mamie Locke (D-Hampton)"
}
],
"committee": "Appropriations",
"full_text": "<p class=enactstm>Be it enacted by the General Assembly of Virginia: <\/p>\n<p class=enactcls>1. That the Code of Virginia is amended by adding in Article 1 of Chapter 34 of Title 38.2 a section numbered <a href='https:\/\/law.lis.virginia.gov\/vacode\/38.2-3407.23\/'>38.2-3407.23<\/a> as follows: <\/p>\n<p class=catchln><ins>\u00a7 <a href='https:\/\/law.lis.virginia.gov\/vacode\/38.2-3407.23\/'>38.2-3407.23<\/a>. Requirements for coverage of medications prescribed for the treatment of cancer and diseases of the blood.<\/ins><\/p>\n<p class=section><ins>A. Each (i) insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-insured basis; <\/ins><ins>(ii) corporation providing individual or group accident and sickness subscription contracts; and (iii) health maintenance organization providing a health care plan for health care services, whose policies, contracts, or plans, including any certificate or evidence of coverage issued in connection with such policies, contracts, or plans, include coverage for drugs prescribed and FDA-approved for the treatment of cancer or diseases of the blood, shall allow, at the patient's direction<\/ins><ins>:<\/ins><\/p>\n<p class=section><ins>1. Provider-administered drugs for the treatment of cancer and diseases of the blood to be dispensed by an in-network treating provider <\/ins><ins>consistent with provider agreement;<\/ins><\/p>\n<p class=section><ins>2. Provider-administered drugs for the treatment of cancer and diseases of the blood to be dispensed by an in-network treating provider <\/ins><ins>when there is a documented delay of at least three days in the delivery of a medication from the designated specialty pharmacy<\/ins><ins>; and<\/ins><\/p>\n<p class=section><ins>3. Self-administered drugs for the treatment of cancer and diseases of the blood to be sent to the pharmacy of the patient's choosing consistent with \u00a7 <a href='https:\/\/law.lis.virginia.gov\/vacode\/38.2-3407.7\/'>38.2-3407.7<\/a>.<\/ins><\/p>\n<p class=section><ins>B. As used in this section, \"prescribed for the treatment of cancer or diseases of the blood\" includes (<\/ins><ins>i<\/ins><ins>) any prescription drug or device prescribed and FDA-approved for the treatment of cancer or diseases of the blood and (<\/ins><ins>ii<\/ins><ins>) any supportive therapies to address or lessen adverse effects attendant to the administration of prescribed drugs, including to anti-emetics, antibiotics, and pain medications.<\/ins><\/p>\n<p class=section><ins>C. Nothing in this section shall prohibit an insurer, health maintenance organization, or pharmacy benefits manager from requiring prior authorization or compliance with a step-therapy protocol for an FDA-approved prescription drug.<\/ins><\/p>\n<p class=section><ins>D. Any payment to the pharmacy or treating provider consistent with this section shall be at the rate set forth in the health insurance issuer's agreement with the treating provider or pharmacy applicable to such drugs, or if no such rate is included in the agreement, then at the national average drug acquisition cost.<\/ins><\/p>\n<p class=section><ins>E. <\/ins><ins>No insurer, health maintenance organization, or pharmacy benefits manager shall penalize, terminate, or otherwise retaliate against an in-network treating provider or pharmacy for exercising rights or providing services consistent with this section.<\/ins><\/p>\n<p class=section><ins>F. The requirements of this section shall apply to all insurance policies, contracts, and plans delivered, issued for delivery, reissued, renewed, or extended or at any time when any term of any such policy, contract, or plan is changed or any premium adjustment is made, on and after the effective date of this section. The provisions of this section shall not apply to short-term travel, accident only, or limited or specified disease policies or contracts, nor to policies or contracts designed for issuance to persons eligible for coverage under Title XVIII of the Social Security Act, known as Medicare, or any other similar coverage under state or federal governmental plans.<\/ins><\/p>\n<p class=section><ins>G. Nothing in this section shall be construed to prohibit a self-insured or self-funded employee welfare benefit plan subject to the Employee Retirement Income Security Act of 1974, P.L. <a href='https:\/\/law.lis.virginia.gov\/vacode\/93-406\/'>93-406<\/a>, 88 Stat. 829, as amended, or any employer sponsoring such plan, from directing, encouraging, or incentivizing enrollees to utilize an onsite pharmacy benefit arrangement or mail<\/ins><ins> order<\/ins><ins> pharmac<\/ins><ins>y<\/ins><ins>, and including through benefit design, cost-sharing differentials, or limited network structure.<\/ins><\/p>",
"catch_line": "Health insurance; coverage of medications prescribed for treatment of cancer & diseases of blood.",
"duplicates": [
{
"year": 2027,
"number": "sb642",
"patron": "Pillion, Todd",
"status": "failed committee",
"chamber": "senate",
"catch_line": "Health insurance; coverage of medications prescribed for treatment of cancer & diseases of blood.",
"date_introduced": "2026-01-14"
}
],
"session_id": 32,
"word_count": 742,
"patron_party": "R",
"patron_place": "Abingdon",
"summary_hash": "a8055ccd3e794a8438fccee626496565",
"patron_prefix": "Sen.",
"patron_suffix": "(R-Abingdon)",
"status_detail": "failed committee",
"_rsun_versions": [
{
"id": "51a0d8042eb704c762e362e12fc40f87646dd5e3ff6a7c6a61b1d3d6953d2847",
"code": "SB642S2",
"bill_id": 85691,
"source_url": null,
"source_date": "2026-02-09",
"source_hash": "391a34260eeffe077a6d65dc7400a6abf431cb983266b8ecc851b555e3540f6e",
"source_html": "<p class=enactstm>Be it enacted by the General Assembly of Virginia: <\/p>\n<p class=enactcls>1. That the Code of Virginia is amended by adding in Article 1 of Chapter 34 of Title 38.2 a section numbered <a href='https:\/\/law.lis.virginia.gov\/vacode\/38.2-3407.23\/'>38.2-3407.23<\/a> as follows: <\/p>\n<p class=catchln><ins>\u00a7 <a href='https:\/\/law.lis.virginia.gov\/vacode\/38.2-3407.23\/'>38.2-3407.23<\/a>. Requirements for coverage of medications prescribed for the treatment of cancer and diseases of the blood.<\/ins><\/p>\n<p class=section><ins>A. Each (i) insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-insured basis; <\/ins><ins>(ii) corporation providing individual or group accident and sickness subscription contracts; and (iii) health maintenance organization providing a health care plan for health care services, whose policies, contracts, or plans, including any certificate or evidence of coverage issued in connection with such policies, contracts, or plans, include coverage for drugs prescribed and FDA-approved for the treatment of cancer or diseases of the blood, shall allow, at the patient's direction<\/ins><ins>:<\/ins><\/p>\n<p class=section><ins>1. Provider-administered drugs for the treatment of cancer and diseases of the blood to be dispensed by an in-network treating provider <\/ins><ins>consistent with provider agreement;<\/ins><\/p>\n<p class=section><ins>2. Provider-administered drugs for the treatment of cancer and diseases of the blood to be dispensed by an in-network treating provider <\/ins><ins>when there is a documented delay of at least three days in the delivery of a medication from the designated specialty pharmacy<\/ins><ins>; and<\/ins><\/p>\n<p class=section><ins>3. Self-administered drugs for the treatment of cancer and diseases of the blood to be sent to the pharmacy of the patient's choosing consistent with \u00a7 <a href='https:\/\/law.lis.virginia.gov\/vacode\/38.2-3407.7\/'>38.2-3407.7<\/a>.<\/ins><\/p>\n<p class=section><ins>B. As used in this section, \"prescribed for the treatment of cancer or diseases of the blood\" includes (<\/ins><ins>i<\/ins><ins>) any prescription drug or device prescribed and FDA-approved for the treatment of cancer or diseases of the blood and (<\/ins><ins>ii<\/ins><ins>) any supportive therapies to address or lessen adverse effects attendant to the administration of prescribed drugs, including to anti-emetics, antibiotics, and pain medications.<\/ins><\/p>\n<p class=section><ins>C. Nothing in this section shall prohibit an insurer, health maintenance organization, or pharmacy benefits manager from requiring prior authorization or compliance with a step-therapy protocol for an FDA-approved prescription drug.<\/ins><\/p>\n<p class=section><ins>D. Any payment to the pharmacy or treating provider consistent with this section shall be at the rate set forth in the health insurance issuer's agreement with the treating provider or pharmacy applicable to such drugs, or if no such rate is included in the agreement, then at the national average drug acquisition cost.<\/ins><\/p>\n<p class=section><ins>E. <\/ins><ins>No insurer, health maintenance organization, or pharmacy benefits manager shall penalize, terminate, or otherwise retaliate against an in-network treating provider or pharmacy for exercising rights or providing services consistent with this section.<\/ins><\/p>\n<p class=section><ins>F. The requirements of this section shall apply to all insurance policies, contracts, and plans delivered, issued for delivery, reissued, renewed, or extended or at any time when any term of any such policy, contract, or plan is changed or any premium adjustment is made, on and after the effective date of this section. The provisions of this section shall not apply to short-term travel, accident only, or limited or specified disease policies or contracts, nor to policies or contracts designed for issuance to persons eligible for coverage under Title XVIII of the Social Security Act, known as Medicare, or any other similar coverage under state or federal governmental plans.<\/ins><\/p>\n<p class=section><ins>G. Nothing in this section shall be construed to prohibit a self-insured or self-funded employee welfare benefit plan subject to the Employee Retirement Income Security Act of 1974, P.L. <a href='https:\/\/law.lis.virginia.gov\/vacode\/93-406\/'>93-406<\/a>, 88 Stat. 829, as amended, or any employer sponsoring such plan, from directing, encouraging, or incentivizing enrollees to utilize an onsite pharmacy benefit arrangement or mail<\/ins><ins> order<\/ins><ins> pharmac<\/ins><ins>y<\/ins><ins>, and including through benefit design, cost-sharing differentials, or limited network structure.<\/ins><\/p>",
"source_metadata": {
"bodyAssociation": "archive-reported-current-version",
"archiveReference": {
"date": "2026-02-09",
"number": "SB642S2"
}
}
}
],
"copatron_count": 1,
"patron_address": [
"851 French Moore Jr. Blvd.",
"Suite 124",
"Abingdon",
"VA 24210"
],
"patron_chamber": "senate",
"patron_started": 2014,
"session_lis_id": 261,
"status_history": [
{
"date": "03\/02\/2026",
"status": "Continued to 2027 in Appropriations (Voice Vote)",
"date_raw": "2026-03-02",
"vote_count": null,
"lis_vote_id": "299852",
"translation": "failed committee"
},
{
"date": "03\/02\/2026",
"status": "Assigned HAPP sub: Compensation and Retirement",
"date_raw": "2026-03-02",
"vote_count": null,
"lis_vote_id": null,
"translation": "in subcommittee"
},
{
"date": "03\/01\/2026",
"status": "Assigned HAPP sub: Health & Human Resources",
"date_raw": "2026-03-01",
"vote_count": null,
"lis_vote_id": null,
"translation": "in subcommittee"
},
{
"date": "02\/27\/2026",
"status": "Assigned HAPP sub: Health & Human Resources",
"date_raw": "2026-02-27",
"vote_count": null,
"lis_vote_id": null,
"translation": "in subcommittee"
},
{
"date": "02\/26\/2026",
"status": "Reported from Labor and Commerce and referred to Appropriations (18-Y 3-N)",
"date_raw": "2026-02-26",
"vote_count": null,
"lis_vote_id": "299360",
"translation": "passed committee"
},
{
"date": "02\/26\/2026",
"status": "Reported from Labor and Commerce",
"date_raw": "2026-02-26",
"vote_count": null,
"lis_vote_id": "299360",
"translation": "passed committee"
},
{
"date": "02\/24\/2026",
"status": "Subcommittee recommends reporting and referring to Appropriations (8-Y 0-N)",
"date_raw": "2026-02-24",
"vote_count": null,
"lis_vote_id": "298812",
"translation": "passed subcommittee"
},
{
"date": "02\/20\/2026",
"status": "Assigned HCL sub: Subcommittee #1",
"date_raw": "2026-02-20",
"vote_count": null,
"lis_vote_id": null,
"translation": "in subcommittee"
},
{
"date": "02\/19\/2026",
"status": "Referred from Health and Human Services and referred to Labor and Commerce (Voice Vote)",
"date_raw": "2026-02-19",
"vote_count": null,
"lis_vote_id": "298212",
"translation": null
},
{
"date": "02\/16\/2026",
"status": "Fiscal Impact Statement from Department of Planning and Budget (SB642)",
"date_raw": "2026-02-16",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/13\/2026",
"status": "Read first time",
"date_raw": "2026-02-13",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/13\/2026",
"status": "Referred to Committee on Health and Human Services",
"date_raw": "2026-02-13",
"vote_count": null,
"lis_vote_id": null,
"translation": "in committee"
},
{
"date": "02\/13\/2026",
"status": "Read first time",
"date_raw": "2026-02-13",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/13\/2026",
"status": "Placed on Calendar",
"date_raw": "2026-02-13",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/10\/2026",
"status": "Read third time and passed Senate Block Vote (40-Y 0-N 0-A)",
"date_raw": "2026-02-10",
"vote_count": null,
"lis_vote_id": "295863",
"translation": "passed senate"
},
{
"date": "02\/10\/2026",
"status": "Engrossed",
"date_raw": "2026-02-10",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Engrossed by Senate - committee substitute (Voice Vote)",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Finance and Appropriations Substitute agreed to",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": "295506",
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Commerce and Labor Substitute rejected",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": "295505",
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Committee substitute reconsidered",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": "295504",
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Engrossed by Senate (Voice Vote)",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": "295507",
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Committee substitute agreed to (Voice Vote)",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Committee substitute rejected (Voice Vote)",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Reconsideration of (40-Y 0-N 0-A)",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Read second time",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/09\/2026",
"status": "Committee substitute printed 26107336D-S2",
"date_raw": "2026-02-09",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "02\/05\/2026",
"status": "Reported from Finance and Appropriations with substitute (15-Y 0-N)",
"date_raw": "2026-02-05",
"vote_count": null,
"lis_vote_id": "294979",
"translation": "passed committee"
},
{
"date": "02\/05\/2026",
"status": "Reported from Finance and Appropriations with substitute",
"date_raw": "2026-02-05",
"vote_count": null,
"lis_vote_id": null,
"translation": "passed committee"
},
{
"date": "02\/02\/2026",
"status": "Fiscal Impact Statement from Department of Planning and Budget (SB642)",
"date_raw": "2026-02-02",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/29\/2026",
"status": "Rereferred to Finance and Appropriations",
"date_raw": "2026-01-29",
"vote_count": null,
"lis_vote_id": null,
"translation": "in committee"
},
{
"date": "01\/29\/2026",
"status": "Motion to rerefer to Finance and Appropriations agreed to",
"date_raw": "2026-01-29",
"vote_count": null,
"lis_vote_id": "293184",
"translation": null
},
{
"date": "01\/29\/2026",
"status": "Commerce and Labor Substitute agreed to",
"date_raw": "2026-01-29",
"vote_count": null,
"lis_vote_id": "293183",
"translation": null
},
{
"date": "01\/29\/2026",
"status": "Motion to rerefer to committee agreed to (Voice Vote)",
"date_raw": "2026-01-29",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/29\/2026",
"status": "Committee substitute agreed to (Voice Vote)",
"date_raw": "2026-01-29",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/29\/2026",
"status": "Read second time",
"date_raw": "2026-01-29",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/28\/2026",
"status": "Passed by for the day",
"date_raw": "2026-01-28",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/28\/2026",
"status": "Passed by for the day Block Vote (Voice Vote)",
"date_raw": "2026-01-28",
"vote_count": null,
"lis_vote_id": "292755",
"translation": null
},
{
"date": "01\/28\/2026",
"status": "Constitutional reading dispensed Block Vote (on 1st reading) (40-Y 0-N 0-A)",
"date_raw": "2026-01-28",
"vote_count": null,
"lis_vote_id": "292754",
"translation": null
},
{
"date": "01\/28\/2026",
"status": "Rules suspended",
"date_raw": "2026-01-28",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/27\/2026",
"status": "Committee substitute printed 26106270D-S1",
"date_raw": "2026-01-27",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/27\/2026",
"status": "Senate committee offered",
"date_raw": "2026-01-27",
"vote_count": null,
"lis_vote_id": null,
"translation": null
},
{
"date": "01\/26\/2026",
"status": "Reported from Commerce and Labor with substitute (15-Y 0-N)",
"date_raw": "2026-01-26",
"vote_count": null,
"lis_vote_id": "292285",
"translation": "passed committee"
},
{
"date": "01\/26\/2026",
"status": "Reported from Commerce and Labor with substitute",
"date_raw": "2026-01-26",
"vote_count": null,
"lis_vote_id": null,
"translation": "passed committee"
},
{
"date": "01\/14\/2026",
"status": "Referred to Committee on Commerce and Labor",
"date_raw": "2026-01-14",
"vote_count": null,
"lis_vote_id": null,
"translation": "in committee"
},
{
"date": "01\/14\/2026",
"status": "Prefiled and ordered printed; Offered 01-14-2026 26105211D",
"date_raw": "2026-01-14",
"vote_count": null,
"lis_vote_id": null,
"translation": "introduced"
}
],
"chief_patron_id": 399,
"date_introduced": "2026-01-14",
"patron_district": 6,
"patron_shortname": "tepillion",
"committee_chamber": "house",
"status_detail_date": "03\/02\/2026",
"committee_shortname": "appropriations",
"patron_name_formatted": "Sen. Todd E. Pillion (R-Abingdon)"
}